Company news
Achieve Life Sciences, Inc. news in 2020
Achieve Life Sciences, Inc.'s news releases, calls and decks from 2020, newest first.
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
December 6, 2020
Achieve Life Sciences Announces Pricing of $15 Million Public Offering
December 2, 2020
Achieve Life Sciences Announces Proposed Public Offering
November 29, 2020
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update
November 11, 2020
Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
October 28, 2020
Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020
October 26, 2020
Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
October 6, 2020
Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
September 29, 2020
Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study
September 17, 2020
Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study
September 17, 2020
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
August 5, 2020
Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering
August 3, 2020
Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
July 30, 2020
Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
July 27, 2020
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
June 28, 2020
Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking
June 28, 2020
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
May 13, 2020
Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020
May 4, 2020
Achieve Life Sciences Announces Private Placement of $1.9 Million
April 29, 2020
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
March 12, 2020
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
March 11, 2020
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020
March 2, 2020
Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users
February 5, 2020
Calls in 2020
Decks in 2020
- IPO Roadshow (November 2020)
IPO roadshow · 32 slides · Nov 30, 2020